A top-5 pharmaceutical company sought to understand differentiating features of competitor COVID-19 vaccine programs and forecast regional market scenarios and commercial implications.
Uncovering Lifecycle Management Options to Maximize the Value of a Novel Antiviral Beyond Treatment of COVID-19
A global pharmaceutical giant engaged Shift Health to explore additional RNA virus indications to inform lifecycle management for a promising antiviral in clinical development for COVID-19.
Leveraging External Partnerships to Maximize the Value of a Top-5 Pharma’s Portfolio
In the face of constrained R&D budgets, a top-5 pharmaceutical company needed support to develop a transformative, corporate-wide strategy to assess and secure external funding.
Developing a Therapeutic Vaccine of Greatest Value to Patients and Systems
A top-5 pharmaceutical company sought the perspectives of payers in the US and major EU markets to ensure that the value of an innovative vaccine would ultimately be recognized by health systems.
Inspiring Urgency Needed to Tackle Alzheimer’s Disease
A top-5 pharmaceutical company needed to prepare decision-makers for the patient and health system impact of disease-modifying therapies and diagnostic biomarkers for Alzheimer’s disease.
Uncovering Risks and Forecasting Performance of a Royalty Portfolio to Guide Investment Decisions
A large institutional investment firm engaged Shift Health to evaluate the products in a portfolio of pharma royalties it had an opportunity to acquire.
Positioning a Global Pharmaceutical Company’s HIV Portfolio to Capture Emerging Opportunities
Shift Health was engaged to support a top-5 global pharmaceutical company in defining its role and priorities in the evolving HIV disease management landscape.
Accelerating R&D Efforts Through Patient Data Repository Partnerships
A multinational pharmaceutical company sought support in developing a strategy to partner with public/academic cancer patient data repositories to advance its own R&D programs.
De-Risking Vaccine Development Through a Translational Research Public-Private Partnership
Facing the need to de-risk the development of new vaccines, a top-10 biopharma company required help articulating the strategic vision and business case for a translational research public-private partnership.